US Penny Stocks To Consider In December 2024

In This Article:

As the U.S. stock market experiences a rise in anticipation of the Federal Reserve's upcoming meeting, with the Nasdaq hitting record highs, investors are exploring diverse opportunities across various sectors. Penny stocks, though often seen as remnants of past market trends, continue to offer intriguing possibilities for those seeking growth at lower entry points. By focusing on smaller or newer companies with strong financials and potential for expansion, investors can uncover valuable opportunities within this segment of the market.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

Inter & Co (NasdaqGS:INTR)

$4.63

$2.03B

★★★★☆☆

QuantaSing Group (NasdaqGM:QSG)

$3.08

$128.29M

★★★★★★

BAB (OTCPK:BABB)

$0.8695

$6.32M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.96

$89.78M

★★★★★★

ZTEST Electronics (OTCPK:ZTST.F)

$0.224099

$8.25M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.48

$48.84M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$0.755

$13.39M

★★★★★☆

Zynerba Pharmaceuticals (NasdaqCM:ZYNE)

$1.30

$65.6M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.8405

$75.59M

★★★★★☆

Click here to see the full list of 720 stocks from our US Penny Stocks screener.

Let's review some notable picks from our screened stocks.

Veru

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Veru Inc. is a late clinical stage biopharmaceutical company that develops medicines for metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS), with a market cap of $105.79 million.

Operations: The company's revenue is primarily derived from its FC2 segment, totaling $14.09 million.

Market Cap: $105.79M

Veru Inc., with a market cap of US$105.79 million, is currently unprofitable and has faced increased losses over the past five years. Despite this, the company shows potential with forecasted revenue growth of 40.82% annually. Recent analysis highlights a reduction in debt to equity ratio and sufficient short-term assets to cover liabilities, indicating some financial stability. However, Veru's cash runway is less than a year if current free cash flow trends continue. The company recently withdrew its US$6.15 million shelf registration filing but presented promising data on enobosarm at recent conferences, showcasing its potential in obesity treatment research.

NasdaqCM:VERU Debt to Equity History and Analysis as at Dec 2024
NasdaqCM:VERU Debt to Equity History and Analysis as at Dec 2024

Duluth Holdings

Simply Wall St Financial Health Rating: ★★★★☆☆